- Home
- XBIO vs RDHL Comparison
XBIO vs RDHL Comparison
Compare XBIO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIO | RDHL |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Israel |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | XBIO | RDHL |
|---|---|---|
| Price | $2.76 | $0.88 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 29.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.99 | $381.91 |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.80 |
| 52 Week High | $13.93 | $3.31 |
Technical Indicators
Market Signals| Indicator | XBIO | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 34.76 |
| Support Level | $2.59 | N/A |
| Resistance Level | $3.21 | $1.07 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 79.64 | 28.70 |
Price Performance
Historical ComparisonAbout XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.